20.07.2016 07:53

Press Release: LifeSci Capital Issues Equity Research Report on Addex Therapeutics


Addex Therapeutics / LifeSci Capital Issues Equity Research Report on Addex Therapeutics . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Geneva, Switzerland, 20 July 2016 - Addex Therapeutics (SIX: ADXN), announced today that the independent life science research firm, LifeSci Capital has issued an equity research report on Addex Therapeutics. The research report highlights the significant potential of Addex portfolio of drug candidates and in particular dipraglurant for Parkinson's disease levodopa-induced dyskinesia.

PD-LID is the most important unmet medical need after a disease-modifying agent for Parkinson's disease. Dipraglurant was awarded orphan drug designation by the US FDA earlier this year and recently completed a receptor occupancy study in collaboration with the Johns Hopkins University and funding from The Michael J. Fox Foundation for Parkinson's Research. LifeSci estimates the US sales of dipraglurant in PD-LID could be as high as US$1.6 billion with a 50% market penetration.

"This equity research report from US based LifeSci Capital provides a useful in depth analysis of the Addex investment case," commented Tim Dyer, CEO of Addex. "With dipraglurant ready to start Phase III in PD-LID and scheduled to start a Phase II POC in focal cervical dystonia, the Addex turnaround is well on track to deliver significant value to our shareholders."

ADX71441, a second Addex drug candidate, recently demonstrated positive results in a non-human primate model of cocaine addiction. This data together with data already generated in nicotine and alcohol use disorder models, shows the broad potential of ADX71441 in these major public health needs.

The full analyst research report is available on www.lifescicapital.com and on Addex website at www.addextherapeutics.com under Investors/downloads/analyst reports.

About LifeSci Capital

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. The firm's service model as a boutique investment bank is unique in that LifeSci exclusively serves emerging life science companies that discover, develop, and commercialize innovative products. LifeSci views its clients as partners, and the firm works closely with them to establish and execute their capital markets strategies. LifeSci's broadly-distributed equity research product is differentiated and provides a deep understanding of its clients' businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the firm's website, www.lifescicapital.com.

About Addex Therapeutics

Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Addex lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a phase IIa POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter phase III for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start phase I and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), alcohol use disorder, cocaine and nicotine dependence. Discovery programs include mGluR4PAM for neurodegenerative diseases, mGluR7NAM for psychosomatic disorders and TrkBPAM for neurodegenerative disorders which are being advanced in collaboration with the Universities of Lausanne and Geneva under the Swiss CTI grant program; and mGluR3PAM which is being advanced in collaboration with Pierre Fabre Pharmaceuticals. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

Press Contacts:

Tim Dyer Chief Executive Officer Addex Therapeutics Telephone: +41 22 884 15 61 Email: PR@addextherapeutics.com

Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Addex Therapeutics via Globenewswire


--- End of Message ---

Addex Therapeutics

12, chemin des Aulx Plan-les-Ouates; Geneva Switzerland

ISIN: CH0029850754;

http://www.addexpharma.com (END) Dow Jones Newswires

   July 20, 2016 01:23 ET (05:23 GMT)- - 01 23 AM EDT 07-20-16

Nachrichten zu Addex Therapeutics Ltd.

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Addex Therapeutics Ltd.

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
14.03.2011Addex Pharmaceuticals holdVontobel Research
23.02.2011Addex Pharmaceuticals holdVontobel Research
15.09.2010Addex Pharmaceuticals holdVontobel Research
29.07.2010Addex Pharmaceuticals holdVontobel Research
28.07.2010Addex Pharmaceuticals holdVontobel Research

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv
14.03.2011Addex Pharmaceuticals holdVontobel Research
23.02.2011Addex Pharmaceuticals holdVontobel Research
15.09.2010Addex Pharmaceuticals holdVontobel Research
29.07.2010Addex Pharmaceuticals holdVontobel Research
28.07.2010Addex Pharmaceuticals holdVontobel Research

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Addex Therapeutics Ltd. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Börse Stuttgart Anlegerclub

Addex Therapeutics Peer Group News

Keine Nachrichten gefunden.

Heute im Fokus

US-Börsen beenden Sitzung in Grün --DAX schließt fester -- Sartorius übertrifft Erwartungen -- METRO senkt Ziele -- Netflix verdient mehr als erwartet -- BioNTech, Apple, Daimler, Commerzbank im Fokus

Scout24 kauft weniger eigene Aktien zurück als angepeilt. ADVA Optical blickt nach gutem Jahresstart etwas optimistischer auf 2021. Anscheinend Thales und andere Unternehmen an HENSOLDT-Beteiligung interessiert. Verizon steigert Umsatz und Gewinn. Bisher 59 Fälle von Hirnthrombosen nach AstraZeneca-Impfung. Deutsche Börse stellt Handel mit Coinbase-Aktie ab Freitag zunächst ein. Continental bekräftigt Ausblick für 2021.


In diesen Städten leben die meisten Milliardäre
In diesen Städten leben die meisten Milliardäre
Die erfolgreichsten Filme aller Zeiten (Stand März 2021)
Welcher Blockbuster spielte den größten Umsatz aller Zeiten ein?
In diesen Sportarten verdient man richtig viel Geld
Mit diesen Sportarten kann man reich werden

Die 5 beliebtesten Top-Rankings

Die ewige DAX-Liga
Welche Aktien sind von Beginn an im deutschen Leitindex notiert?
James Bond und seine Autos
Welcher Sportwagen gehörte zu welchem Bond-Film?
Die 10 beliebtesten Serien laut IMDb
Diese Serien haben die besten User-Bewertungen.
Rohstoffe: Die Gewinner und Verlierer in Q1 2021
Welcher Rohstoff macht das Rennen?
Rentendauer in Europa: So viel Zeit hat man, um die Rente zu genießen
Lohnt sich die Rente
mehr Top Rankings


Die STIKO hält Impfangebote für alle bis zum Ende des Sommers nach wie vor für realistisch. Würden Sie dieses - gleichgültig welcher Impfstoff - annehmen?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!



Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln